Handelen Precigen, Inc. - PGEN CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.05 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Precigen Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.18 |
Open* | 1.14 |
1-Jaarlijkse Verandering* | -5% |
Dagelijks bereik* | 1.1 - 1.19 |
52 wekelijks bereik | 0.81-2.90 |
Weekgemiddelde volume (10 dagen) | 970.06K |
Gemiddeld volume (3 maanden) | 31.09M |
Marktkapitalisatie | 311.69M |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 255.48M |
Omzet | 23.25M |
EPS | -0.38 |
Dividend (opbrengst %) | N/A |
Beta | 1.96 |
Volgende inkomsten datum | Aug 7, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
May 26, 2023 | 1.19 | 0.02 | 1.71% | 1.17 | 1.20 | 1.10 |
May 25, 2023 | 1.18 | -0.12 | -9.23% | 1.30 | 1.30 | 1.18 |
May 24, 2023 | 1.30 | -0.08 | -5.80% | 1.38 | 1.40 | 1.24 |
May 23, 2023 | 1.36 | 0.10 | 7.94% | 1.26 | 1.42 | 1.26 |
May 22, 2023 | 1.28 | 0.01 | 0.79% | 1.27 | 1.32 | 1.25 |
May 19, 2023 | 1.27 | 0.05 | 4.10% | 1.22 | 1.28 | 1.21 |
May 18, 2023 | 1.22 | 0.00 | 0.00% | 1.22 | 1.25 | 1.17 |
May 17, 2023 | 1.20 | 0.02 | 1.69% | 1.18 | 1.21 | 1.15 |
May 16, 2023 | 1.20 | 0.05 | 4.35% | 1.15 | 1.22 | 1.13 |
May 15, 2023 | 1.19 | 0.15 | 14.42% | 1.04 | 1.22 | 1.03 |
May 12, 2023 | 1.04 | -0.07 | -6.31% | 1.11 | 1.11 | 1.02 |
May 11, 2023 | 1.11 | -0.03 | -2.63% | 1.14 | 1.14 | 1.10 |
May 10, 2023 | 1.18 | -0.07 | -5.60% | 1.25 | 1.25 | 1.10 |
May 9, 2023 | 1.24 | 0.01 | 0.81% | 1.23 | 1.24 | 1.18 |
May 8, 2023 | 1.23 | 0.07 | 6.03% | 1.16 | 1.25 | 1.16 |
May 5, 2023 | 1.19 | 0.02 | 1.71% | 1.17 | 1.22 | 1.15 |
May 4, 2023 | 1.18 | -0.01 | -0.84% | 1.19 | 1.19 | 1.14 |
May 3, 2023 | 1.19 | 0.09 | 8.18% | 1.10 | 1.20 | 1.10 |
May 2, 2023 | 1.10 | -0.03 | -2.65% | 1.13 | 1.17 | 1.10 |
May 1, 2023 | 1.15 | -0.02 | -1.71% | 1.17 | 1.19 | 1.12 |
Precigen, Inc. Events
Tijd (UTC) (UTC) | Land | Evenement |
---|---|---|
Thursday, June 8, 2023 | ||
Tijd (UTC) (UTC) 13:00 | Land US
| Evenement Precigen Inc Annual Shareholders Meeting Precigen Inc Annual Shareholders MeetingForecast -Previous - |
Friday, June 9, 2023 | ||
Tijd (UTC) (UTC) 13:00 | Land US
| Evenement Precigen Inc Annual Shareholders Meeting Precigen Inc Annual Shareholders MeetingForecast -Previous - |
Monday, August 7, 2023 | ||
Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q2 2023 Precigen Inc Earnings Release Q2 2023 Precigen Inc Earnings ReleaseForecast -Previous - |
Tuesday, November 7, 2023 | ||
Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q3 2023 Precigen Inc Earnings Release Q3 2023 Precigen Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totale inkomsten | 26.909 | 14.267 | 103.178 | 90.722 | 151.178 |
Inkomsten | 26.909 | 14.267 | 103.178 | 90.722 | 151.178 |
Kosten van opbrengsten, totaal | 6.339 | 5.745 | 55.513 | 61.401 | 62.676 |
Brutowinst | 20.57 | 8.522 | 47.665 | 29.321 | 88.502 |
Totale bedrijfskosten | 102.635 | 106.215 | 189.781 | 257.511 | 520.845 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 48.006 | 51.994 | 91.704 | 98.634 | 125.162 |
Onderzoek & Ontwikkeling | 47.17 | 47.933 | 41.644 | 66.666 | 333.007 |
Bedrijfsresultaat | -75.726 | -91.948 | -86.603 | -166.789 | -369.667 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -5.779 | -18.587 | -17.087 | -16.211 | 1.558 |
Overige, Netto | 1.539 | -0.432 | -0.165 | 11.736 | -27.803 |
Netto inkomen voor belastingen | -79.966 | -110.967 | -103.855 | -171.264 | -395.912 |
Netto inkomen na belastingen | -79.777 | -110.807 | -103.773 | -170.334 | -380.487 |
Minderheidsbelang | 0 | 1.592 | 5.37 | ||
Equity In Affiliates | |||||
Netto inkomen voor extra. Posten | -79.777 | -110.807 | -103.773 | -168.742 | -375.117 |
Netto inkomen | 28.317 | -92.166 | -170.521 | -322.324 | -509.336 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -79.777 | -110.807 | -103.773 | -168.742 | -375.117 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 28.317 | -92.166 | -170.521 | -322.324 | -509.336 |
Verwaterd Netto Inkomen | 28.317 | -92.166 | -170.521 | -322.324 | -509.336 |
Verwaterd Gewogen Gemiddelde Aandelen | 200.361 | 197.76 | 167.066 | 154.139 | 129.522 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.39817 | -0.56031 | -0.62115 | -1.09474 | -2.89617 |
Verwaterde Genormaliseerde Winst per Aandeel | -0.39453 | -0.55853 | -0.61757 | -0.96482 | -2.89617 |
Ongebruikelijke uitgaven (inkomsten) | 1.12 | 0.543 | 0.92 | 30.81 | 0 |
Totale buitengewone posten | 108.094 | 18.641 | -66.748 | -153.582 | -134.219 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totale inkomsten | 1.851 | 1.763 | 16.722 | 2.911 | 5.513 |
Inkomsten | 1.851 | 1.763 | 16.722 | 2.911 | 5.513 |
Kosten van opbrengsten, totaal | 1.527 | 1.257 | 1.577 | 1.811 | 1.694 |
Brutowinst | 0.324 | 0.506 | 15.145 | 1.1 | 3.819 |
Totale bedrijfskosten | 25.275 | 23.56 | 24.336 | 27.073 | 27.666 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 11.639 | 11.51 | 10.137 | 12.67 | 13.689 |
Onderzoek & Ontwikkeling | 12.163 | 10.793 | 12.622 | 11.954 | 11.801 |
Bedrijfsresultaat | -23.424 | -21.797 | -7.614 | -24.162 | -22.153 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.309 | -0.634 | -1.118 | -2.026 | -2.001 |
Overige, Netto | 0.326 | 0.263 | 1.038 | 0.04 | 0.198 |
Netto inkomen voor belastingen | -22.789 | -22.168 | -7.694 | -26.148 | -23.956 |
Netto inkomen na belastingen | -22.734 | -22.176 | -7.644 | -26.059 | -23.898 |
Netto inkomen voor extra. Posten | -22.734 | -22.176 | -7.644 | -26.059 | -23.898 |
Totale buitengewone posten | 0 | 0 | 95.023 | 8.424 | 4.647 |
Netto inkomen | -22.734 | -22.176 | 87.379 | -17.635 | -19.251 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -22.734 | -22.176 | -7.644 | -26.059 | -23.898 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -22.734 | -22.176 | 87.379 | -17.635 | -19.251 |
Verwaterd Netto Inkomen | -22.734 | -22.176 | 87.379 | -17.635 | -19.251 |
Verwaterd Gewogen Gemiddelde Aandelen | 229.77 | 200.675 | 200.671 | 200.461 | 199.629 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.09894 | -0.11051 | -0.03809 | -0.13 | -0.11971 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Verwaterde Genormaliseerde Winst per Aandeel | -0.0991 | -0.11051 | -0.03809 | -0.12793 | -0.11814 |
Ongebruikelijke uitgaven (inkomsten) | -0.054 | 0 | 0 | 0.638 | 0.482 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totaal vlottende activa | 118.159 | 156.628 | 148.948 | 234.643 | 285.483 |
Geldmiddelen en kortetermijnbeleggingen | 55.95 | 108.663 | 100.117 | 75.053 | 216.874 |
Geldmiddelen & Equivalenten | 4.858 | 36.423 | 51.792 | 65.793 | 96.876 |
Korte Termijn Investeringen | 51.092 | 72.24 | 48.325 | 9.26 | 119.998 |
Totale Vorderingen, Netto | 13.804 | 1.98 | 20.427 | 26.228 | 26.565 |
Accounts Receivable - Trade, Net | 0.978 | 1.414 | 16.506 | 21.25 | 25.308 |
Total Inventory | 0.287 | 0.326 | 11.359 | 16.097 | 20.575 |
Prepaid Expenses | 4.779 | 5.471 | 7.192 | 6.444 | 5.327 |
Other Current Assets, Total | 43.339 | 40.188 | 9.853 | 110.821 | 16.142 |
Total Assets | 215.977 | 359.856 | 314.587 | 455.763 | 716.177 |
Property/Plant/Equipment, Total - Net | 15.415 | 18.589 | 44.277 | 86.197 | 86.896 |
Property/Plant/Equipment, Total - Gross | 38.854 | 40.046 | 79.229 | 135.329 | 135.946 |
Accumulated Depreciation, Total | -23.439 | -21.457 | -34.952 | -49.132 | -49.05 |
Goodwill, Net | 36.923 | 37.554 | 54.363 | 63.754 | 93.627 |
Intangibles, Net | 44.455 | 52.291 | 65.396 | 68.346 | 88.962 |
Long Term Investments | 0 | 48.562 | 0 | 1.461 | 2.779 |
Other Long Term Assets, Total | 1.025 | 46.232 | 1.603 | 1.362 | 158.43 |
Total Current Liabilities | 78.645 | 34.645 | 42.127 | 122.912 | 61.562 |
Accounts Payable | 4.068 | 3.112 | 4.598 | 5.917 | 11.973 |
Accrued Expenses | 31.333 | 17.066 | 20.303 | 30.322 | 28.96 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 1.922 | 0.466 |
Current Port. of LT Debt/Capital Leases | 43.219 | 0.052 | 0.36 | 31.67 | 0.479 |
Other Current Liabilities, Total | 0.025 | 14.415 | 16.866 | 53.081 | 19.684 |
Total Liabilities | 89.718 | 252.508 | 247.413 | 384.052 | 353.322 |
Total Long Term Debt | 0 | 179.882 | 171.522 | 186.321 | 211.216 |
Long Term Debt | 0 | 179.882 | 171.522 | 186.321 | 211.216 |
Deferred Income Tax | 2.263 | 2.539 | 2.897 | 2.834 | 3.856 |
Minority Interest | 0 | 15.867 | |||
Other Liabilities, Total | 8.81 | 35.442 | 30.867 | 71.985 | 60.821 |
Total Equity | 126.259 | 107.348 | 67.174 | 71.711 | 362.855 |
Common Stock | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 1998.31 | 2022.7 | 1886.57 | 1752.05 | 1722.01 |
Retained Earnings (Accumulated Deficit) | -1868.57 | -1915.56 | -1823.39 | -1652.87 | -1330.55 |
Other Equity, Total | -2.728 | 0.534 | 3.984 | -27.475 | -28.551 |
Total Liabilities & Shareholders’ Equity | 215.977 | 359.856 | 314.587 | 455.763 | 716.177 |
Total Common Shares Outstanding | 208.15 | 206.74 | 187.663 | 163.275 | 160.02 |
Unrealized Gain (Loss) | -0.76 | -0.331 | 0.013 | 0.007 | -0.061 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totaal vlottende activa | 137.743 | 118.159 | 162.806 | 164.619 | 154.937 |
Geldmiddelen en kortetermijnbeleggingen | 104.091 | 55.95 | 71.327 | 115.297 | 112.142 |
Geldmiddelen & Equivalenten | 9.74 | 4.858 | 9.067 | 43.844 | 40.321 |
Korte Termijn Investeringen | 94.351 | 51.092 | 62.26 | 71.453 | 71.821 |
Totale Vorderingen, Netto | 15.522 | 13.804 | 2.454 | 1.871 | 24.866 |
Accounts Receivable - Trade, Net | 1.771 | 0.978 | 1.194 | 1.325 | 24.323 |
Total Inventory | 0.287 | 0.219 | 0.224 | 12.73 | |
Prepaid Expenses | 4.33 | 4.779 | 6.363 | 2.654 | 5.199 |
Other Current Assets, Total | 13.8 | 43.339 | 82.443 | 44.573 | |
Total Assets | 241.546 | 215.977 | 259.245 | 321.224 | 335.568 |
Property/Plant/Equipment, Total - Net | 14.525 | 15.415 | 16.439 | 16.67 | 44.546 |
Property/Plant/Equipment, Total - Gross | 38.519 | 38.854 | 39.097 | 38.859 | 85.021 |
Accumulated Depreciation, Total | -23.994 | -23.439 | -22.658 | -22.189 | -40.475 |
Goodwill, Net | 36.966 | 36.923 | 36.713 | 36.864 | 53.613 |
Intangibles, Net | 43.848 | 44.455 | 42.416 | 45.933 | 51.427 |
Long Term Investments | 7.46 | 0 | 0 | 11.877 | 29.914 |
Other Long Term Assets, Total | 1.004 | 1.025 | 0.871 | 45.261 | 1.131 |
Total Current Liabilities | 46.733 | 78.645 | 104.864 | 29.901 | 25.601 |
Accounts Payable | 3.809 | 4.068 | 4.201 | 2.668 | 4.415 |
Accrued Expenses | 29.09 | 31.333 | 18.518 | 15.563 | 18.136 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 13.819 | 43.219 | 82.069 | 0 | 0.355 |
Other Current Liabilities, Total | 0.015 | 0.025 | 0.076 | 11.67 | 2.695 |
Total Liabilities | 57.413 | 89.718 | 116.713 | 265.571 | 261.732 |
Total Long Term Debt | 0 | 0 | 0 | 198.674 | 201.112 |
Long Term Debt | 0 | 0 | 198.674 | 201.112 | |
Deferred Income Tax | 2.239 | 2.263 | 2.092 | 2.26 | 2.438 |
Other Liabilities, Total | 8.441 | 8.81 | 9.757 | 34.736 | 32.581 |
Total Equity | 184.133 | 126.259 | 142.532 | 55.653 | 73.836 |
Common Stock | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 2078.13 | 1998.31 | 1996.1 | 1993.98 | 1991.67 |
Retained Earnings (Accumulated Deficit) | -1891.3 | -1868.57 | -1846.39 | -1933.77 | -1916.14 |
Unrealized Gain (Loss) | -0.498 | -0.76 | -1.236 | -1.335 | -1.133 |
Other Equity, Total | -2.201 | -2.728 | -5.945 | -3.221 | -0.566 |
Total Liabilities & Shareholders’ Equity | 241.546 | 215.977 | 259.245 | 321.224 | 335.568 |
Total Common Shares Outstanding | 255.483 | 208.15 | 208.15 | 208.15 | 207.693 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | 28.317 | -92.166 | -170.521 | -323.916 | -514.706 |
Geldmiddelen uit Operationele Activiteiten | -65.045 | -55.771 | -77.021 | -135.927 | -124.24 |
Geldmiddelen uit Operationele Activiteiten | 10.765 | 13.761 | 17.516 | 24.896 | 33.112 |
Deferred Taxes | -0.15 | -0.167 | -0.156 | -3.674 | -21.278 |
Niet-Geldelijke Posten | -81.278 | 23.605 | 96.791 | 164.338 | 398.617 |
Cash Taxes Paid | 0 | 0.036 | 0.048 | 0.05 | 0.216 |
Contant Betaalde Rente | 8.535 | 7.155 | 7.202 | 3.751 | 3.868 |
Veranderingen in het Operationeel Kapitaal | -22.699 | -0.804 | -20.651 | 2.429 | -19.985 |
Geldmiddelen uit Investeringsactiviteiten | 226.417 | -74.54 | 27.779 | 86.851 | -151.213 |
Kapitaaluitgaven | -4.924 | -7.247 | -7.527 | -37.883 | -41.587 |
Overige Cash Flow investeringsposten, Totaal | 231.341 | -67.293 | 35.306 | 124.734 | -109.626 |
Geldmiddelen uit Financieringsactiviteiten | -155.292 | 121.187 | 32.705 | 8.138 | 309.795 |
Financiering van Cash Flow Posten | -0.588 | 0 | 0 | ||
Uitgifte (Aflossing) van aandelen, netto | 0.001 | 121.653 | 35.117 | 6.924 | 90.326 |
Uitgifte (Aflossing) van Schulden, Netto | -154.705 | -0.466 | -2.412 | 1.214 | 219.469 |
Wisselkoerseffecten | -0.827 | 0.217 | 0.353 | -0.81 | 0.295 |
Nettowijziging in Geldmiddelen | 5.253 | -8.907 | -16.184 | -41.748 | 34.637 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -22.734 | 28.317 | 50.493 | -36.886 | -19.251 |
Cash From Operating Activities | -18.388 | -65.045 | -49.649 | -25.836 | -18.783 |
Cash From Operating Activities | 1.711 | 10.765 | 9.044 | 6.518 | 3.292 |
Deferred Taxes | -0.055 | -0.15 | -0.162 | -0.112 | -0.058 |
Non-Cash Items | 3.401 | -81.278 | -84.085 | 9.832 | 5.629 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | |
Cash Interest Paid | 0.924 | 8.535 | 8.187 | 3.568 | 3.535 |
Changes in Working Capital | -0.711 | -22.699 | -24.939 | -5.188 | -8.395 |
Cash From Investing Activities | -50.408 | 226.417 | 214.996 | 33.141 | 16.568 |
Capital Expenditures | -0.154 | -4.924 | -4.871 | -3.297 | -1.579 |
Other Investing Cash Flow Items, Total | -50.254 | 231.341 | 219.867 | 36.438 | 18.147 |
Cash From Financing Activities | 44.174 | -155.292 | -116.01 | -0.276 | -0.163 |
Issuance (Retirement) of Stock, Net | 73.501 | 0.001 | 0.001 | 0.001 | 0.001 |
Issuance (Retirement) of Debt, Net | -29.27 | -154.705 | -116.011 | -0.277 | -0.164 |
Foreign Exchange Effects | -0.028 | -0.827 | -0.804 | -0.471 | -0.23 |
Net Change in Cash | -24.65 | 5.253 | 48.533 | 6.558 | -2.608 |
Financing Cash Flow Items | -0.057 | -0.588 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
Third Security, LLC | Venture Capital | 37.7505 | 96445913 | 85470 | 2023-03-09 | LOW |
Merck Serono SA | Corporation | 8.0816 | 20647152 | 0 | 2022-12-31 | |
Miller Value Partners, LLC | Investment Advisor | 3.7199 | 9503782 | 9503782 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.2901 | 8405732 | 1327932 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.6141 | 6678607 | 1808746 | 2023-03-31 | LOW |
Iridian Asset Management LLC | Investment Advisor/Hedge Fund | 1.3971 | 3569266 | 689654 | 2023-03-31 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0324 | 2637666 | 745952 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.8683 | 2218230 | 213565 | 2023-03-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.8575 | 2190790 | 1457587 | 2023-03-31 | HIGH |
Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 0.7887 | 2014894 | 2014894 | 2023-03-31 | MED |
Patient Capital Management, LLC | Investment Advisor | 0.5729 | 1463760 | 665560 | 2023-03-31 | |
BofA Global Research (US) | Research Firm | 0.5129 | 1310411 | 1198195 | 2023-03-31 | LOW |
Sabzevari (Helen) | Individual Investor | 0.4778 | 1220786 | 283173 | 2023-03-31 | LOW |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.4348 | 1110963 | 0 | 2023-03-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.4095 | 1046318 | 245441 | 2023-03-31 | LOW |
SEI Investments Management Corporation | Investment Advisor/Hedge Fund | 0.4091 | 1045167 | 227852 | 2023-03-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.405 | 1034598 | 277166 | 2023-03-31 | LOW |
MSD Partners, L.P. | Investment Advisor | 0.3758 | 960000 | 0 | 2023-03-31 | LOW |
D. E. Shaw & Co., L.P. | Hedge Fund | 0.2973 | 759484 | 13000 | 2023-03-31 | LOW |
Nuveen LLC | Pension Fund | 0.2676 | 683585 | 137667 | 2023-03-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group530K+
Handelaren
87K+
Actieve klanten per maand
$46M+
Maandelijks beleggingsvolume
$31M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Precigen, Inc. Company profile
Over Precigen, Inc.
Precigen, Inc. (Precigen) is een bedrijf actief in de synthetische biologie dat zich toelegt op zijn activiteiten in het ontdekkings- en klinische stadium om gen- en celtherapieën te ontwikkelen voor de behandeling van immuno-oncologie, auto-immuunziekten en infectieziekten. Zijn therapeutische platforms, waaronder UltraCAR-T, AdenoVerse immunotherapie en ActoBiotics, zijn ontworpen om het niveau en de fysiologische locatie van genexpressie nauwkeurig te controleren en biologische moleculen te wijzigen om de functie en output van levende cellen te controleren en zo onderliggende ziekteomstandigheden te behandelen. De belangrijkste klinische programma's van de Vennootschap, waaronder: PRGN-3005, PRGN-3006, en PRGN-3007, die gebouwd zijn op haar UltraCAR-T platform; PRGN-2009 en PRGN-2012, die gebaseerd zijn op haar AdenoVerse immunotherapie platform; en AG019, dat gebouwd is op haar ActoBiotics platform. Het bedrijf voltooide ook een Fase I studie van INXN-4001, een niet-viraal plasmide DNA met drievoudige werking, dat is gebouwd op zijn UltraVector-platform. Het heeft ook een robuuste pijplijn van preklinische programma's.
Industry: | Pharmaceuticals (NEC) |
20374 Seneca Meadows Parkway
GERMANTOWN
MARYLAND 20876
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 530.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen